Jupiter Merlin Backs Woodford fund
Jupiter’s John Chatfeild-Roberts-led Merlin multi-manager team have bought into Neil Woodford’s Equity Income fund, while continuing to back his successor at Invesco Perpetual Mark Barnett.
Neil Woodford
-
-
Woodford unveils bearish portfolio
Neil Woodford has published full details of what appears the bearish composition of his CF Woodford Equity Income Fund.
-
Woodford reveals all but is not yet cruising
“We have taken off and we have already gained a lot of height, but we are not yet at cruising altitude,” says Neil Woodford of his new fund. But what do his initial positions represent to sceptical investors still waiting at check-in?
-
Woodford hires social responsibility head
Newly formed Woodford Investment Management has appointed a head of corporate social responsibility.
-
Woodford and Barnett targeted
They say imitation is the sincerest form of flattery, but UK equity income stars Neil Woodford and Mark Barnett will be less than impressed by spoof Twitter accounts that have sprung up in their name.
-
Equity income holds firm in the face of Woodford
Low rates, fund launches and the inexorable drive for yield have focused investor attention on income funds, but do they stand up to the scrutiny?
-
Woodford on sciences business conversion chasm
In his second piece from the Woodford Investment Roadshows, Gary Corcoran looks at Woodford’s views on AstraZeneca, research and Britain’s track record of converting great science into great business.
-
Woodford applauds AstraZeneca board
Woodford applauds the AstraZeneca board’s handling of Pfizers takeover approach
-
Woodfords HSBC stake first bank buy since 03
Woodford Investment Managements Neil Woodford says he started dipping his toe into the financial counter midway through last year.
-
ON THE ROAD Neil Woodford on the consensus mistake
Neil Woodford is back and within 24 hours of leaving Invesco was in the limelight following his decision to form a new company, Woodford Investment Management and launch a new fund.
-
Pa analysis valuing astra zeneca without woodford
The battle for AstraZeneca between Pfizer, the UK government and the existing shareholders of both companies is, as far as investors are concerned, all about its valuation - nothing more, nothing less.
-
Woodford Investment Management chooses PA
Woodford Investment Management Portfolio Adviser launch roundtable series to introduce Neil Woodford to its core readership.
Other titles in the PA universe
